Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Details Narrative)

v3.19.1
Stockholders' Equity (Details Narrative) - USD ($)
 2 Months Ended 12 Months Ended
May 25, 2018
Sep. 29, 2017
Jun. 29, 2018
Dec. 31, 2018
Dec. 31, 2017
Preferred stock, shares authorized       10,000,000 10,000,000
Preferred stock, par value       $ 0.0001 $ 0.0001
Conversion debt into shares   1,850,625      
Common stock, shares authorized       350,000,000 43,261,049
Common stock, par value       $ 0.0001 $ 0.0001
Contractual obligation amount $ 82,502        
Clinical Trial Funding commitment       $ 1,800,000  
Private Placement [Member]          
Common stock and a warrant purchase price per share       $ 0.01  
Stock issued during period convertible securities       $ 20,000,000  
Private Placement [Member] | Maximum [Member]          
Common stock and a warrant purchase price per share       $ 2.27  
2018 Private Placement Transactions [Member]          
Number of units sold     1,402,442    
Purchase price per unit     $ 2.27    
Gross proceeds from unit sold     $ 3,200,000    
Common stock and a warrant purchase price per share     $ 2.724    
Amount paid to placement agent     $ 167,526    
Issued placement agent warrants to purchase shares     84,146    
Warrant term     3 years    
Contractual obligation amount     $ 141,304    
PoC Capital, LLC [Member]          
Number of units sold 792,952        
Purchase price per unit $ 2.724        
Common stock and a warrant purchase price per share $ 2.724        
Amount paid to placement agent $ 108,000        
Issued placement agent warrants to purchase shares 47,578        
Contractual obligation amount $ 60,457        
Amount financed under agreement $ 1,800,000        
Warrant to purchase common stock 792,952        
Warrant expiration date Jul. 29, 2021        
Pledge Agreement with PoC [Member]          
Number of units sold 396,476        
Amount paid to placement agent $ 720,000        
Pledge Agreement with PoC [Member] | Tranche One [Member]          
Number of units sold 198,238        
Pledge Agreement with PoC [Member] | Tranche Two [Member]          
Number of units sold 198,238        
Common Stock [Member]          
Conversion debt into shares   102,789      
Subscription Receivable [Member]          
Clinical Trial Funding commitment       $ 1,800,000  
Heatwurx Shareholders [Member] | Series D Preferred Stock [Member]          
Conversion debt into shares   178,924      
Accrued dividends   $ 118,658      
CRO [Member]          
Repayment of releated party debt       $ 239,129